

## Corrigendum

# Enteral metronidazole for the prevention of graft-versus-host disease in pediatric marrow transplant recipients: results of a pilot study

SL Guthery, JE Heubi and A Filipovich

*Bone Marrow Transplantation* (2005) **36**, 371.  
doi:10.1038/sj.bmt.1705076

**Correction to:** *Bone Marrow Transplantation* (2004) **33**, 1235–1239. doi:10.1038/sj.bmt.1704474; published online 12 April 2004

In regards to Table 3 in the above-referenced manuscript, the reported hazard ratio, parameter estimate, and 95% confidence intervals are incorrect for the variable unrelated donor. The parameter estimates for enteral metronidazole and age are also incorrect. A corrected version is presented. These changes do not alter our conclusions. The authors regret this error.

**Table 3** Multivariable analysis

	<i>Parameter estimate</i>	<i>Hazard ratio (95% CI)</i>	<i>P-value</i>
Enteral metronidazole	−1.03	0.36 (0.13–0.997)	0.05
<i>In vivo</i> immunosuppression only	1.33	3.78 (1.86–7.66)	0.0002
Unrelated donor	0.61	1.85 (0.994–3.43)	0.05
Age ≥5.9 years (vs age <5.9 years)	0.58	1.79 (0.995–3.22)	0.05

Risk of GvHD is reduced among those treated with metronidazole, following adjustment for GVH prophylaxis, unrelated donor status, and age at transplantation.